Pfizer and Soligenix committed to making an impact in the pharmaceutical space by improving access to treatments.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer and Soligenix committed to making an impact in the pharmaceutical space by improving access to treatments.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Soligenix (United States)
company in Princeton, United States
Nothing else this week.
Related events
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.
- Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.
- Pfizer is jointly marketing the drug Eliquis.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
Coverage
Newest first; wire copies grouped- CNW GroupLate-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas NetworkNewsWire Editorial Coverage NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare d